Philip Morris International Inc.
As of Fiscal Year 2025 (ended December 31, 2025)
Key KPIs at a Glance
| Metric | Value |
|---|---|
| Total net revenue (FY2025) | $40.65 billion, up 7% year-over-year (up 6.5% organic) |
| Smoke-free product net revenue (FY2025) | $16.9 billion, 41.5% of total net revenue, up 15% year-over-year |
| Reported operating income (FY2025) | $14.89 billion, up from $13.40 billion in FY2024 |
| Net income (FY2025) | approximately $11.3 billion, up about 61% year-over-year from $7.06 billion in FY2024 |
| Reported diluted EPS (FY2025) | $7.26, up 61% from $4.52 in FY2024 |
| Adjusted diluted EPS (FY2025) | $7.54, up 15% from $6.57 in FY2024 |
| IQOS heated tobacco unit shipments (FY2025) | 155.1 billion units, up 11% year-over-year |
| ZYN nicotine pouch shipments (FY2025) | 794 million cans |
| ZYN U.S. oral nicotine value share (FY2025, company estimate) | approximately two-thirds, per PMI's own disclosure |
| Employees (as of December 31, 2025) | approximately 84,900 |
Sources: Figures are from Philip Morris International's Q4/FY2025 earnings release (SEC Form 8-K Exhibit 99.1, reported February 6, 2026) and 2025 Annual Report/10-K. The net-income figure is corroborated across secondary financial-data sources rather than quoted verbatim from a primary income-statement line, but is consistent with the primary source's reported EPS and share count. PMI does not disclose a dollar-value revenue split between IQOS (heated tobacco) and ZYN (oral nicotine pouches) within its smoke-free total -- only shipment volumes are broken out. ZYN's cited ~two-thirds U.S. value share is PMI's own claim, not an independently attributed third-party estimate.